Pharmacological Innovations for posttraumatic stress disorder and medication-enhanced psychotherapy

Current Pharmaceutical Design

Volumn 18, Issue 35, 2012, Pages 5645-5658

  Dunlop, Boadie W ^a   Mansson, Erika ^a   Gerardi, Maryrose ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic beta antagonists; Anti anxiety agents; Antidepressants; Corticotropinreleasing hormone; Glucocorticoids; Memory; Psychotherapy; PTSD

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 AMINOBUTYRIC ACID; APREPITANT; CARVEDILOL; CYCLOSERINE; DIAZEPAM; DOPAMINE; ENDOCANNABINOID; ESZOPICLONE; GLUTAMIC ACID; HYDROCORTISONE; METHYLENE BLUE; MIFEPRISTONE; NEPICASTAT; NEUROKININ; NEUROSTEROID; OMEGA 3 FATTY ACID; ORVEPITANT; OXYTOCIN; PRAZOSIN; PREDNISONE; PREGNENOLONE; PROPRANOLOL; PRX 03140; RAPAMYCIN; SUBSTANCE P; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERUCERFONT; VOFOPITANT; YOHIMBINE;

ADRENERGIC SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; FEAR; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEARNING; MEMORY; MEMORY CONSOLIDATION; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DESIGN; FEAR; HUMANS; MOLECULAR TARGETED THERAPY; PSYCHOTHERAPY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84866534160     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803530899     Document Type: Review

References (160)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-27.
2. Mletzko TC, Dunlop BW. In: Szirmai, A., ed. The transformation of post-traumatic stress disorder: From neurosis to neurobiology. Rijecka, Croatia: Anxiety and Related Disorders. 2011; pp. 151-90.
3. Sareen J, Houlahan T, Cox B, Asmundson GJG. Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis 2005; 193: 450-4.
4. Sareen J, Cox BJ, Stein MB, Afif TO, Fleet C, Asmundson GJG. Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med 2007; 69: 242-8.
5. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD).Cochrane DB Syst Rev 2006; (1):CD002795.
6. th edition), American Psychiatric Association, Washington, D.C., 1994.
7. Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. Prog Neuropsychopharm Biol Psychiatry 2009; 33: 169-80.
8. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. Am J Psychiatry 2003; 160: 371-3.
9. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with posttraumatic stress disorder. Biol Psychiatry 2007; 61: 928-34.
10. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. Biol Psychiatry 2008; 63; 629-32.
11. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 892-7.
12. Ahearn EP, Juergens T, Cordes T, Becker T, Krahn D. A review of atypical antipsychotic medications for posttraumatic stress disorder. Int Clin Psychopharmacol 2011; 26: 193-200.
13. Krystal JH, Rosenheck RA, Cramer JA. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. JAMA 2011; 306: 493-502.
14. Duncan E, Dunlop BW, Boshoven W, Woolson S, Hamer R, Phillips L. Relative risk of glucose elevation during antipsychotic exposure in a VA population. Int Clin Psychopharmacol 2007; 22:1-11.
15. Duncan EJ, Woolson, SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol 2009; 24:204-13.
16. Davis LL, Davidson JRT, Ward LC, Bartolucci A., Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmcol 2008; 28: 84-8.
17. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 201-6.
18. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45: 1226-9.
19. Myers KM, Carlezon WA, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology Rev 2011; 36:274-93.
20. Shin LM, Liberzon I. The neurocircuitry of fear, stress and anxiety disorders. Neuropsychopharmacology 2010; 35: 169-91.
21. Etkin, A., Wager, T.D. Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and social phobia. Am J Psychiatry 2007; 164, 1476-88.
22. Radley JJ, Gosseline KL, Sawchenko PE. A discrete GABAergic relay mediates medial prefrontal cortical inhibition of the neuroendocrine stress response. J Neurosci 2009; 29: 7330-40.
23. Jodoj E, Chiang C, Aston-Jones C. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus ceruleus neurons. Neuroscience 1998; 83: 63-79.
24. Dunn AJ, Swiergiel AH, Palamarchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann NY Acad Sci 2004; 1018: 25-34.
25. Gresack JE, Risbrough VB. Corticotropin-releasing factor and noradrenergic signaling exert reciprocal control over startle reactivity. Int J Neuropsychopharmacol 2011; 14: 1179-94.
26. Vythilingam M, Anderson GM, Owens MH, et al. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. J Clin Endocrinol Metab 2000; 85: 4138-45.
27. Delahanty DL, Nugent NR. Predicting PTSD prospectively based on prior trauma history and immediate biological responses. Ann NY Acad Sci 2006; 1071:27-40.
28. Geracioti TD Jr, Baker DG, Kasckow JW, et al. Effects of traumarelated audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in posttraumatic stress disorder. Psychoneuroendocrinology 2008; 33: 416-24.
29. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003, 54: 947-9.
30. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554-65.
31. Pacak K, Palkovits M, Kopin IJ, Goldstein DS. Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. Front Neuroendocrinol 1995; 16: 89-150.
32. de Kloet CS, Vermetten E, Geuze E, Kavelaars A, Heijnen CJ, Westenberg HG. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. J Psychiat Res 2006; 40: 550-67.
33. Mehta D, Binder E. Gene x environment vulnerability factors for PTSD: the HPA axis. Neuropharmacology 2012; 62: 654-62.
34. Van Emmerik AAP, Kamphuis JH, Hulsbosch AM, Emmelkamp PMG. Single session debriefing after psychological trauma: a metaanalysis. Lancet 2002; 360:766-71.
35. Breslau N, Peterson EL, Schultz LR. A second look at prior trauma and the posttraumatic stress disorder effects of subsequent trauma: A prospective epidemiologic study. Arch Gen Psychiatry 2008; 65: 431-7.
36. Pitman RK. Post-traumatic stress disorder, hormones and memory. Biol Psychiatry 1989; 26: 221-3.
37. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of- concept trial in physically injured patients. J Traumatic Stress 2007; 20: 923-32.
38. Hoge EA, Worthington JJ, Nagurney JT, et al. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther 2012; 18(1): 21-7.
39. Witteveen AB, Huizink AC, Slottje P, et al. Associations of cortisol with posttraumatic stress symptoms and negative life events: a study of police officers and firefighters. Psychoneuroenocrinology 2010; 35: 1113-8.
40. McFarlane AC, Barton CA, Yehuda R, Wittert G. Cortisol response to acute trauma and risk of posttraumatic stress disorder. Psychoneuroendocrinology 2011; 36: 720-7.
41. De Bellis MD, Baum AS, Birmaher B, et al. A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems. Biol Psychiatry 1999; 45: 1259-70.
42. Delahanty DL, Nugent NR, Christopher NC, Walsh M. Initial urinary epinephrine and cortisol levels predict acute PTSD symptoms in child trauma victims. Psychoneuroendocrinology 2005; 30: 121-8.
43. McGaugh JL, Roozendaal B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr Op Neurobiol 2002; 12: 205-10.
44. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories and symptoms of posttraumatic stress disorder in patients after cardiac surgery: A randomized study. Biol Psychiatry 2004; 55: 627-33.
45. Weis F, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone reduce chronic stress symptoms and improve health related quality of life in high-risk patients after cardiac surgery: a randomized study. J Thorac Cardiovas Surg 2006; 131: 277-82.
46. Zohar J, Yahalom H, Kozlovsky N, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. Eur Neurospyschopharmacol 2011; 21: 796-809.
47. Adamec R, Fougere D, Risbrough V. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD. Int J Neuropsychopharmacol 2010; 13: 747-57.
48. Roozendaal B, Quirarte GL, McGaugh JL. Glucocorticoids interact with the basolateral amygdala -adrenoreceptor-cAMP/cAMP/PKA system in influencing memory consolidation. Eur J Neurosci 2002; 12: 553-60.
49. Cohen H, Matar MA, Buskila D, Kaplan Z, Zohar J. Early poststressor intervention with high-dose corticosterone attenuates posttraumatic stress responses in an animal model of posttraumatic stress disorder. Biol Psychiatry, 2008; 64: 708-17.
50. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010; 31: 736-56.
51. Missig G, Ayers LW, Schulkin J, Rosen JB. Oxytocin reduces background anxiety in a fear-potentiated startle paradigm. Neuropsychopharmacology 2010; 35: 2607-16.
52. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003; 54: 1389-98.
53. Petrovic P, Kalisch R, Singer T, Dolan RJ. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci 2008; 28: 6607-15.
54. Pitman RK, Orr SP, Lasko NB. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 1993; 48: 107-17.
55. Meyer-Lindenberg A. Impact of prosocial neuropeptides on human brain function. Prog Brain Res. 2008; 170: 463-70.
56. Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005; 30: 924-9.
57. Olff M, Langeland W, Wiitteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr 2010; 15: 522-30.
58. Heim C, Young DJ, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry 2009; 14: 954-8.
59. Makkar SR, Zhang SQ, Cranney J. Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation and extinction of fear memory. Neuropyschopharmacology 2010; 35: 1625-52.
60. Bustos SG, Maldonado H, Molina VA. Midazolam disrupts fear memory reconsolidation. Neuroscience 2006; 139: 831-42.
61. Zhang S, Cranney J. The role of GABA and anxiety in the reconsolidation of conditioned fear. Behav Neurosci 2008; 122: 1295-305.
62. Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Hashimoto K, Hamazaki T. Omega-3 fatty acids for secondary prevention of posttraumatic stress disorder after accidental injury: an open-label pilot study. J Clin Psychopharmacol 2010; 30: 217-9.
63. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139: 991-7.
64. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 2008; 155: 751-9.
65. Kitamura T, Saitoh Y, Takeshima N, et al. Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory. Cell. 2009; 139: 814-27.
66. Holbrook TL, Galarneau MR, Quinn K, Doughterty AL. Morphine use after combat injury in Iraq and post-traumatic stress disorder. New Eng J Med 2010; 362: 110-7.
67. Bryant RA, Cremer M, O'Donnell M, Silove D, McFarlane AC. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009; 65: 438-40.
68. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluovoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder. J Clin Psychopharmacol 2006; 26: 152-56.
69. Petrakis IL, Ralevski E, Desai N, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology 2012; 37(4): 996-1004.
70. Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008; 41: 8-18.
71. Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006; 163: 2186-8.
72. Stanley WC, Li B, Bonhaus DW. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-hydroxylase. Br J Pharmacol 1997; 121: 1803-9.
73. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-37.
74. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.
75. Shen F, Smith JA, Chang R, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 2011; 61: 69-79.
76. Lovallo WR, Robinson JL, Glahn DC, Fox PT. Acute effects of hydrocortisone on the human brain: an fMRI study. Psychoneuroendocrinologylogy 2010; 35: 15-20.
77. Merz CJ, Tabbert K, Schweckendiek J, et al. Investigating the impact of sex and cortisol on implicit fear conditioning with fMRI. Psychoneuroendocrinologylogy 2010; 35: 33-46.
78. Aerni A, Traber R, Hock C. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 2004; 161: 1488-90.
79. Kuhlmann S, Krischbaum C, Wolf OT. Effects of oral cortisol treatment in healthy young women on memory retrieval of negative and neutral words. Neurobiol Learn Mem 2005; 83: 158-62.
80. Miller MW, McKinney AE, Kanter FS, Korte KJ, Lovallo WR. Hydrocortisone suppression of the fear-potentiated startle response and posttraumatic stress disorder. Psychoneuroendocrinology 2011; 36: 970-80.
81. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999; 46: 1480-508.
82. Bremner J, Licinio J, Darness A, et al. Elevated CSF corticotropinreleasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997; 154: 624-9.
83. Sautter F, Bissette G, Wiley J, et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 2003; 54: 1382-8.
84. Baker D, West S, Nicholson W, et al. Serial CSF corticotropinreleasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999; 156: 585-8.
85. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 2002; 22: 193-9.
86. Ladd C, Huot R, Thrivikraman K, Nemeroff C, Meaney M, Plotsky P. Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 2000; 122: 81-103.
87. Plotsky P, Thrivikraman K, Nemeroff C, Caldji C, Sharma S, Meaney M. Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology 2005; 30: 2192-204.
88. McGhee LL, Maani CV, Garza TH, Gaylord KM, Black IH. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 2008; 64 (2 Suppl): S195-8.
89. Aleksandrovskii Iu A, Avedisova AS, Boev IV, et al. Efficacy and tolerability of coaxil (tianeptine) in the therapy of posttraumatic stress disorder. Zh Nevrol Psikhiatr Im S S Korsakova 2005; 105: 24-9.
90. Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry 2006; 21: 174-9.
91. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237-49.
92. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinologylogy 2003; 28: 139-68.
93. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003; 21: 245-54.
94. Gunn BG, Brown AR, Lambert JJ, Belelli D. Neurosteroids and GABA-A receptor interactions: a focus on stress. Front Neurosci 2011; 5:131.
95. Reddy DS. Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113-37.
96. Eser D, Baghai TC, Schule C, Nothdurfter C, Rupprecht R. Neuroactive steroids as endogenous modulators of anxiety. Curr Pharmaceutical Design 2008; 14: 3525-33.
97. Strohle A, Romeo E, di Michele F, et al. Induced panic attacks shift -aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003; 60: 161-8.
98. Gee KW, McCauley LD, Nan LC. A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 1995; 9: 207-27.
99. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009; 325 (5939):490-3.
100. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry. CNS Drugs 2005; 19: 275-93.
101. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31: 251-72.
102. Ebner K, Rupniak NMJ, Saria A, Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101: 4280-5.
103. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011; 21: 221-9.
104. Geracioti TD Jr., Carpenter LL, Owens MJ, et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006; 163: 637-43.
105. Bonne O, Gill MG, Luckenbaugh DA, et al. Corticotropinreleasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry 2011; 72: 1124-8.
106. Fujimura Y, Yasuno F, Farris A, et al. Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry 2009; 66:94-7.
107. Michelgard A, Appel L, Pissiota A, et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 2007; 61: 1002-6.
108. Furmark T, Appel L, Michelgard A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram or placebo. Biol Psychiatry 2005; 58: 132-42.
109. Keller M, Montgomery S, Ball W. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216-23.
110. Glaxo Smith Kline [homepage on the internet]. Result Summary for 113211. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=113211&studyId=69BEE7E776F9-4595-8D33-AC49CFDABCF2&compound=orvepitant. Accessed Jan 18, 2012.
111. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236-8.
112. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression. Prim Care Companion J Clin Psychiatry 2008; 10: 222-8.
113. Jia F, Goldstein PA, Harrison NL. The modulation of GABA(A) receptors in the thalamus by eszopiclone and zolpidem. J Pharmacol Exp Ther 2009; 328:1000-6.
114. A receptors containing the alpha-5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci 2004; 20: 1928-36.
115. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005; 30: 516-24.
116. Lin HC, Mao SC, Gean PW. Effects of intra-amygdala infusion of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn Mem 2006; 13: 316-21.
117. Fraser, GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009; 15: 84-8.
118. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2011; epub ahead of print.
119. Cohen S. The therapeutic potential of LSD-25. In: Featherstone RM, Simon A, eds. A Pharmacologic Approach to the Study of the Mind. Thomas: Sprinfield, IL, 1959; pp. 251-8.
120. Bouton ME. Context and behavioral processes in extinction. Learn Mem 2004; 11: 485-94.
121. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56-72.
122. Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci 2009; 12: 256-8.
123. Tronson NC, Taylor JR. Molecular mechanisms of memory reconsolidation. Nat Rev Neurosci 2007; 8: 262-75.
124. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-44.
125. Gurguis GN, Vitton BJ, Uhde TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 1997; 16:27-39.
126. Southwick SM, Morgan CA, Charney DS, High JR. Yohimbine use in a natural setting: effects on posttraumatic stress disorder. Biol Psychiatry 1999; 46: 442-4.
127. Cain CK, Blouin AM, Barad M. Adrenergic transmission facilitates extinction of conditioned fear in mice. Learn Mem 2004; 11: 179-87.
128. Holmes A, Quirk GJ. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders the case of yohimbine. Trends Pharmacol Sci 2009; 131: 2-6.
129. Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anx Disord 2009; 23: 350-6.
130. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012; 96: 32-45.
131. Ohlow MJ, Moosmann B. Phenothiazine: the seven lives of pharmacology's first lead structure Drug Discov Today 2011; 16: 119-31.
132. Visarius TM, Stucki JW, Lauterburg BH. Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 1997; 412: 157-60.
133. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 2004; 77: 175-81.
134. Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 2004; 11: 633-40.
135. Wrubel KM, Barrett D, Shumake J, Johnson SE, Gonzalez-Lima F. Methylene blue facilitates the extinction of fear in an animal model of susceptibility to learned helplessness. Neurobiol Learn Mem 2007; 87: 209-17.
136. Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F. The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav 2007; 86:712-7.
137. McGaugh JL, Roozendaal B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr Op Neurobiol 2002; 12: 205-10.
138. Yang YL, Chao PK, Lu KT. Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 2006; 31:912-24.
139. Roozendaal B, Williams CL, McGaugh JL. Glucocoritcoid receptor activation in the rat nucleus of the solitary tract facilitates memory consolidation: involvement of the basolateral amygdala. Eur J Neurosci 1999; 11: 1317-23.
140. Roozendaal B, Brunson KI, Holloway BI, McGaugh JL, Baram TZ. Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci USA 2002; 99: 13908-13.
141. De Quervain D J-F, Bentz D, Michael T, et al. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 2011; 108: 6621-5.
142. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U et al. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 2006; 103: 5585-90.
143. Bentz D, Michael T, de Quervain D J-F, Wilhelm FH. Enhancing exposure therapy for anxiety disorders with glucocorticoids: From basic mechanisms of emotional learning to clinical applications. J Anxiety Disord 2010; 24: 223-30.
144. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiological responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psych Res 2008; 42: 503-6.
145. Pitman RK, Milad MR, Igoe SA. Systemic mifepristone blocks reconsolidation of cue-conditioned fear; propranolol prevents this effect. Behav Neurosci 2011; 125:632-8.
146. Blundell J, Kouser M, Powell CM. Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Nuerobiol Learn Mem 2008; 90: 28-35.
147. Tang SJ, Reis G, Kange H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to longterm synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99: 467-72.
148. Glover EM, Ressler KJ, Davis M. Differing effects of systemically administered rapamycin on consolidation and reconsolidation of context vs. cued fear memories. Learn Mem 2010; 17: 577-81.
149. Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci 2006; 26: 12977-83.
150. Parrott AC. The psychotherapeutic potential of MDMA (3,4- methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 2007; 191: 181-93.
151. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4- methylenedioxymethamphetamine (Ecstasy) in healthy volunteers. J Psychopharmacol 2000;14: 269-74.
152. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161-8.
153. Johansen PO, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol 2009; 23:389-91.
154. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomomized controlled pilot study. J Psychopharmacol 2011; 25: 439-52.
155. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 2003; 55: 463-508.
156. Whitaker-Azmita PM, Aronson TA. "Ecstasy" (MDMA)-induced panic. Am J Psychiatry 1989; 146: 119.
157. Sprague TD, Nichols DE. The monoamine oxidase-B inhibitor Ldeprenyl protects against 3,4-methylenedioxymethamphetamineinduced lipid peroxidation and long-term serotonergic deficits. J Pharmaol Exp 1995; 273: 667-73.
158. Colado MI, O'Shea E, Granados R, Esteban B, Martin AB, Green AR. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4- methylenedioxymethamphetamine (MDMA or "ecstasy") administration. Br J Pharmacol 1999; 126: 911-24.
159. Davison D, Parrott AC, Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Human Psychopharmacol 1997; 12: 221-6.
160. Jovanovic T, Kazama A, Bachevalier J, Davis M. Impaired safety signal learning may be a biomarker of PTSD. Neuropharmacology 2012; 62:695-704.